FDA to Regulate E-Cigarettes, Hookahs

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the FDA that subject e-cigarettes and hookahs to some of the same regulations as tobacco products.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the US Food and Drug Administration for e-cigarettes and hookahs.

For example, the new rules would require a valid photo ID for purchasing e-cigarettes and hundreds of e-cigarette products will now require regulatory review in order to stay on the market.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
Satri-cel Improves Survival vs Physician’s Choice in Pretreated G/GEJ Cancer

Satri-cel Improves Survival vs Physician’s Choice in Pretreated G/GEJ Cancer

Tim Cortese
June 9th 2025
Article

Satri-cel led to a median PFS of 3.25 months vs 1.77 months with physician’s choice in patients with pretreated gastric or gastroesophageal cancer.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

Sacituzumab Tirumotecan Enhances Efficacy in Pretreated EGFR-Mutant NSCLC

Roman Fabbricatore
June 9th 2025
Article

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Socazolimab Exhibits Overall Survival Benefit Vs Placebo in ES-SCLC

Roman Fabbricatore
June 7th 2025
Article

The addition of socazolimab to carboplatin plus etoposide was well tolerated compared with placebo in patients with extensive-stage small cell lung cancer.

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.